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Abstract: A Surface Plasmon Resonance Imaging (SPRI) sensor based on bromelain or chymopapain or ficin
has been developed for specific cystatin determination. Cystatin was captured from a solution by immobilized
bromelain or chymopapain or ficin due to the formation of an enzyme-inhibitor complex on the biosensor sur-
face. The influence of bromelain, chymopapain or ficin concentration, as well as the pH of the interaction on the
SPRI signal, was investigated and optimized. Sensor dynamic response range is between 0–0.6 mg/ml and the
detection limit is equal to 0.1 mg/ml. In order to demonstrate the sensor potential, cystatin was determined in
blood plasma, urine and saliva, showing good agreement with the data reported in the literature. (Folia His-
tochemica et Cytobiologica 2012, Vol. 50, No. 1, 130–136)
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Introduction
Cystatins are a widespread group of proteins with
protective and control functions. They are cysteine
protease inhibitors such as cathepsins which pro-
tect organisms from the dangerous activity of en-
zymes and reduce the risk of diseases. Lowered or
raised concentrations of cystatin may be a symp-
tom of many disorders [1–3]. Located in the hu-
man body, where cystatin is present, are the secret-
ed tissue of epithelium cells, nervous tissue, pros-
tate cells and body fluids [4, 5]. Its shortage or ex-
cess may indicate some sicknesses [4, 6]. The
normal cystatin range in blood plasma is 0.53–0.92
μg/ml, and a lower concentration of this protein
may indicate cancerous diseases [7, 8]. The normal
range level of cystatin in human saliva is 0.36–4.8
μg/ml; values below this range indicate a caries oc-
currence [9, 10]. Human urine cystatin concentra-
tion varies between 0.033 and 0.29 μg/ml. A higher
cystatin level in urine is characteristic of people with
kidney disease or of older age [11].
Cystatin C is one of the representatives of the
cystatin superfamily. It is a low molecular weight
protein (M = 13.3 kDa) and consists of a single
polypeptide chain containing 120 aminoacids. It is
produced by all nucleated cells in the body and se-
creted into the extracellular matrix in invariant
quantities [12]. Cystatin C is freely filtered by the
glomerulus and undergoes resorption and degra-
dation in proximal tubular cells. The blood level of
this protein is correlated with the glomerular fil-
tration rate and can be used as a marker of the
glomerular filtration rate (GFR). Measurement of
the cystatin C level is simpler and more effective
than the determination of creatinine. Recently, it
has been shown that determination of cystatin C in
serum is a better marker of GFR than serum crea-
tinine [13, 14].
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The Surface Plasmon Resonance Imaging tech-
nique has been successfully applied for the determi-
nation of biologically active substances such as cathe-
psins B [15], G [16], and D, E [17]. These determina-
tions were performed by the application of highly spe-
cific biosensors for each kind of cathepsin. Biosensors
were prepared by immobilization onto gold chip sur-
face inhibitors specific for each kind of cathepsin. Due
to the specific interaction of the immobilized inhibi-
tor with a specific cathepsin, only this cathepsin is
captured and then determined by SPRI. Immobilized
cystatin was applied for cathepsin determination [15].
However, the same interaction can be used for cysta-
tin determination.
Bromelain, ficin and chymopapain are a family
of enzymes known as the cysteine proteases. The
action mechanism of these enzymes is quite similar.
Of this group, only bromelain is widely known and
applied.
Bromelain (E.C. 3.4.22.4) belongs to a papain su-
perfamily, but differs from the other members of the
superfamily in terms of the amino acid sequence [18].
Bromelain is a 23.8 kDa — basic thiol protease which
contains 212 amino acid residues with a single N-gly-
coside oligosaccharide chain [19–21]. Bromelain can
be isolated from pineapple (Ananas comosus) [22, 23].
It is worth stressing that bromelain has a therapeutic
application [22, 24, 25].
Ficin (EC 3.4.22.3) is also a cysteine sulfhydryl
enzyme which is isolated from fig latex. It is very of-
ten used for differentiating blood group antigens. As
with bromelain or papain, ficin takes part in esters
hydrolysis and catalyzes the process of peptide syn-
thesis [26]. Ficin predicts the degradability of proteins
of ruminal feeds [27].
Chymopapain (EC 3.4.22.6) is a plant cysteine
protease obtained from the latex of the Carica papa-
ya [28]. It is provided as a mixture of proteolytic en-
zymes [29] or its salts [30]. This enzyme has some bio-
medical applications [29, 30]. Application of chymo-
papain decreased dramatically after reports of side
effects [29]. Chymopapain is used in contact lens liq-
uids [31].
The pharmaceutical application of the papain
group of enzymes is limited because of the relatively
poor stability of the aqueous solutions [32].
The aim of this paper was the manufacture of bio-
sensors for cystatin determination on the basis of spe-
cific cystatin interaction with bromelain or ficin or
chymopapain. The further aim was optimization of
biosensor conditions, demonstration of the ability for
determination of cystatin in body fluids, such as blood
plasma, urine and saliva, as well as comparison of
three developed biosensors.
Material and methods
Chemicals and materials. Cysteamine hydrochloride, cys-
tatin from chicken egg white (12.5 kDa), human albumin,
bromelain from pineapple stem, ficin from fig tree latex,
chymopapain from papaya latex, N-Ethyl-N’-(3-dimethyl
aminopropyl) carbodiimide (EDC), HEPES sodium salt
(all SIGMA, Steinheim, Germany) and N-Hydroxysuccin-
imide (NHS) (ALDRICH, Munich, Germany) were used,
as well as dichloroethane of HPLC grade (FLUKA, Mu-
nich, Germany), absolute ethanol, sodium hydroxide, so-
dium chloride, sodium carbonate, sodium phosphate, po-
tassium phosphate, sodium acetate, potassium chloride,
magnesium chloride (all POCh, Gliwice, Poland), acetic
buffer pH = 3.79–5.57, Phosphate Buffered Saline (PBS)
pH = 7.2 (BIOMED, Lublin, Poland), phosphate buffer
pH = 7.17–8.04, and carbonate buffer pH = 8.50–9.86.
Photopolymer ELPEMER SD 2054 and hydrophobic pro-
tective paint SD 2368 UV SG-DG (PETERS, Kempen,
Germany) chemicals were used as received. Aqueous so-
lutions were prepared with filtered milliQ water
(Simplicity®MILLIPORE).
Blood samples were taken from the Blood Donor Cen-
ter at Bialystok, Poland. Urine samples were taken from
healthy people younger and older than 75. Saliva samples
were taken from healthy people.
Procedures. Chip preparation. Glass plates with layers of
chromium and gold were manufactured as described in
a previous paper [33]. The gold surface of the chip was cov-
ered with photopolymer and hydrophobic paint as described
in a previous paper [34]. The chip has four parts of 12 free
gold surfaces. Twelve single SPRI measurements can be
performed for a single sample. Measurements can be done
without mixing the tested solutions.
Enzyme immobilization. Chips were rinsed with ethanol and
water and dried under a stream of nitrogen. They were then
immersed in 20 mM of cysteamine ethanolic solutions for 2 h
and then rinsed with ethanol and water and once again dried
under a stream of nitrogen. Bromelain was activated with
NHS (50 mM) and EDC (200 mM) solution in a carbonate
buffer (pH = 8.5) environment and incubated on the amine-
modified surface at 37°C for 1 h [33, 34]. Ficin and chymo-
papain were immobilized in the same way.
SPRI measurements. SPRI measurements were performed
as described in a previous paper [33, 34]. Reflectivity was
simultaneously measured across an entire chip surface at
a fixed angle of incident light for different samples and de-
pends on the kind and number of biomolecules captured by
the sensor. The contrast values obtained for all pixels across
a particular sample spot were integrated. Thus the SPRI
signal was integrated over the spot area. NIH Image J ver-
sion 1.32 software was used to evaluate the SPRI images in
2D form.
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Preparation of biological samples. Blood plasma. Samples
of blood plasma were prepared as described in a previous
paper [35]. 2 ml of blood was centrifuged and filtered for
blood plasma separation from hemoglobin. The prepared
plasma of blood was diluted twice with a PBS buffer and
transferred onto the sensor surface for 10 minutes. After
interaction, the surface of the biosensor was washed six times
with HEPES buffer. The concentration was evaluated us-
ing a chicken egg white cystatin calibration curve.
Urine. Samples of urine were prepared as described in
a previous paper [35]. Urine was centrifuged and the super-
natant filtered. Prepared urine samples were transferred
onto the sensor surface for 10 minutes. After interaction,
the surface of the biosensor was washed six times with the
HEPES buffer. The concentration was evaluated using
a chicken egg white cystatin calibration curve.
Saliva. Samples of saliva were prepared as described in
a previous paper [35]. 3 ml of saliva was centrifuged and the
supernatant filtered. Prepared saliva samples were diluted
five times with a PBS buffer and transferred onto the sen-
sor surface for 10 minutes. After interaction, the surface of
the biosensor was washed six times with the HEPES buffer.
The concentration was evaluated using a chicken egg white
cystatin calibration curve.
Results
The influence of bromelain, chymopapain
and ficin concentration on the analytical
signal of cystatin
The purpose of these experiments was the selection
of the optimal conditions for cystatin determination,
separately for bromelain, chymopapain and ficin.
The influence of bromelain, chymopapain and ficin
concentration on the SPRI signal was studied separate-
ly for each enzyme. The experiments were performed
at constant cystatin concentration. Eight enzyme solu-
tions with different concentrations (0.2; 0.38; 0.75; 1.0;
1.5; 2.0; 2.25; and 3.0 μg/ml), preliminarily activated with
NHS and EDC, were transferred onto different places
on the chip surface modified by cysteamine. After en-
zyme immobilization, the chip was treated with the chick-
en egg white cystatin solution (0.75 μg/ml). The time of
the interaction was 10 minutes. The chip was then rinsed
with the HEPES buffer, dried and the SPRI measure-
ment performed. The results are shown in Figure 1.
Curves ‘,b’ and ‘,a’ are shifted upwards in order to avoid
coincidence of these curves with curve ‘,c’. The obtained
curve shape is of a Langmuir isotherm type. The pla-
teau of the signal is observed for enzyme concentration
above 1 mg/ml. Concentration of bromelain, chymopa-
pain and ficin equal to 1.5 mg/ml was selected as optimal
for further investigation.
The influence of solution pH on the interaction process
The influence of pH of a cystatin solution on the SPRI
signal was studied within a range of 1.0–11.0 at con-
stant concentrations of bromelain, chymopapain or
ficin (1.5 mg/ml) and cystatin (0.75 mg/ml). Solutions
of the enzyme preliminarily activated with EDC and
NHS were transferred onto different places on the
chip surface modified by cysteamine. After inhibitor
immobilization, the biosensor was treated for 10 min-
utes with chicken egg white cystatin solutions having
different pH values. Results are shown in Figure 2.
The obtained figure shows that the maximum of the
SPRI signal for the enzyme — cystatin complex is
between 6.3 and 6.6. The value of pH = 6.5 was se-
lected as optimal for further investigation.
Analytical response of the developed three sensors to
cystatin concentration. Calibration curve
A response of the analytical SPRI signal for chicken
egg white cystatin concentration was measured with-
in the range of cystatin concentration between 0.1 and
1.4 mg/ml at the same pH value (6.5). The chip sur-
faces modified by cysteamine were covered by layers
of ficin (1.5 mg/ml). Cystatin solutions with different
concentrations were put on immobilized ficin for 10
minutes. The obtained calibration curve is shown in
Figure 3a. The experiments with chymopapain and
bromelain were performed analogically. The results
are shown in Figures 3b and 3c respectively.
Specificity of the enzyme — cystatin interaction
Specificity of the interaction between bromelain, fi-
cin, chymopapain and cystatin was verified through
Figure 1. Dependence of the enzyme — cystatin complex
SPRI signal (arbitrary units) on inhibitor concentration:
(a) bromelain, (b) ficin, (c) chymopapain. Initial cystatin
concentration: 0.75 μg/ml. Initial pH of cystatin solution: 7.0
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treating a surface of the chip with immobilised en-
zyme layer (1.5 mg/ml) by human albumin (0.4 mg/
/ml), free chicken egg white cystatin (0.4 mg/ml) and
an enzyme-cystatin complex (0.4:0.7 mg/ml). The
time of the interaction was 10 minutes. Results are
shown in Figure 4.
Precision of the developed method
for cystatin determination
Precision of the developed method was tested under
optimal conditions (pH of cystatin solution: 6.5, bro-
melain, ficin, chymopapain concentration: 1.5 mg/ml)
for the concentration of chicken egg white cystatin
equal to 0.4 mg/ml. The results of measurements are
shown in Table 1.
Cystatin determination in real samples
Blood plasma samples
Samples of blood plasma from nine healthy adult do-
nors were analyzed using the developed sensors for cys-
tatin determination. The results are shown in Table 2.
Urine samples
The developed sensor was also used to determine
cystatin concentration in urine. Samples were taken
Figure 2. Dependence of the enzyme — cystatin complex
SPRI signal (arbitrary units) on pH. Initial (a) bromelain,
(b) chymopapain, (c) ficin concentration: 1.5 mg/ml. Initial
cystatin concentration: 0.75 mg/ml
Figure 3. The dependence of the enzyme – cystatin
complex SPRI signal (arbitrary units) on cystatin concen-
tration. The initial enzyme (a) ficin, (b) chymopapain,
(c) bromelain concentration: 1.5 mg/ml. The initial pH
value of cystatin solution: 6.5. (a) Example linear section of
curve (a); concentration range 0–0.6 mg/ml
Figure 4. SPRI signals corresponding to the interaction
between immobilized enzyme: (a) bromelain, (b) ficin,
(c) chymopapain, and different molecules (chicken egg
white cystatin or complex cystatin with bromelain or human
albumin). Initial concentration of enzyme: 1.5 mg/ml. Initial
concentration of cystatin and albumin: 0.4 mg/ml.
The initial pH value of cystatin and albumin solutions: 6.5
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from people younger and older than 75. The results
are shown in Table 3.
Saliva samples
Cystatin was determined in six samples of saliva in or-
der to demonstrate the developed sensor applicability
for this purpose. The results are shown in Table 4.
Discussion
All three calibration curves of chicken egg white cysta-
tin are of the Langmuir’s isotherm type (see Figure 3).
The roughly linear sections of these curves (following
Henry’s isotherm) is within the range of 0–0.6 mg/ml
(0–45 mM) and are useful for analytical purposes (see the
example of the section of curve ‘a’). It is worth stressing
that calibration curves for three sensors are almost identi-
cal and are indistinguishable due to precision error.
As can be concluded from Figure 4, the developed
sensor reacts to free cystatin and, to a much smaller
degree, to the presence of cystatin bounded in the com-
plex with bromelain, ficin or chymopapain. The bars
corresponding to the analytical signals of complex are
significantly lower than the signals for free cystatin. This
is evidence that the complexes of bromelain, ficin or
chymopapain are stable (dissociation constans 8.4·10–8
M for ficin, 9.5·10–8 M for bromelain [36] and 9·10–13 M
for chymopapain [37]). Any response to human albu-
min was not observed, which is evidence of the speci-
ficity of the enzyme — cystatin interaction.
The results in Table 1 show that the precision of
SPRI measurement using the developed biosensor is
10.3% for sensor based on bromelain, 7.8% on ficin
and 12.9% on chymopapain, which are values typical
for trace analysis. Confidence limits of the results
(0.08 mg/ml for bromelain, 0.06 mg/ml for ficin and
0.10 mg/ml for chymopapain) can be easily narrowed
by the application of measurement repetitions at the
same chip surface.
All three sensors gave very similar results concern-
ing cystatin concentration in the blood plasma of
healthy donors (see Table 2). The obtained results for
cystatin in the blood plasma are within a range be-
tween 0.59 and 0.88 mg/ml. All results are within the
norm range (0.53–0.92 mg/ml) reported in the litera-
ture [7, 8].
In all cases, the results concerning the cystatin
concentration in the urine of donors younger and old-
er than 75 obtained with three sensors exhibit similar
values (see Table 3). The cystatin level in all investi-
gated urine samples was within the norm range
Table 1. Precision of measurement of concentration of chicken egg white cystatin
Chicken egg No of meas. Added Found Recovery S.D. RSD Confidence limit
white cystatin  [mg/ml]  [mg/ml]  (%)  [mg/ml] (%)  (95%) [mg/ml]
Sensor based on 24 0.400 0.390 97.50 0.04 10.3 0.08
bromelain
Sensor based on 24 0.400 0.386 96.50 0.03 7.8 0.06
ficin
Sensor based 24 0.400 0.387 96.75 0.05 12.9 0.10
on chymopapain
Table 2. Cystatin concentration in blood plasma of healthy donors as determined using three different sensors
Donor number Cystatin concentration in blood plasma [mg/ml]
Sensor based on bromelain Sensor based on ficin Sensor based on chymopapain
1 0.75 ± 0.05 0.76 ± 0.06 0.74 ± 0.05
2 0.79 ± 0.04 0.79 ± 0.05 0.80 ± 0.04
3 0.70 ± 0.04 0.71 ± 0.08 0.70 ± 0.04
4 0.62 ± 0.06 0.61 ± 0.05 0.63 ± 0.04
5 0.59 ± 0.05 0.62 ± 0.07 0.62 ± 0.02
6 0.73 ± 0.06 0.71 ± 0.05 0.72 ± 0.04
7 0.88 ± 0.05 0.86 ± 0.03 0.89 ± 0.04
8 0.76 ± 0.04 0.76 ± 0.03 0.75 ± 0.06
9 0.88 ± 0.02 0.87 ± 0.08 0.88 ± 0.04
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(0.033–0.29 mg/ml) reported in the literature [9, 11].
Theoretically, urine from older people should con-
tain higher cystatin concentrations, but this is not the
rule and may depend on many factors [9].
In all cases, the results concerning the cystatin
concentration in the saliva of donors obtained with
three different sensors exhibit similar values (see Ta-
ble 4). The norm range of cystatin concentration in
saliva reported in the literature is between 0.36 and
4.8 mg/ml and all measured values are within this range
[9]. Higher cystatin concentration in saliva could be
a caries symptom [10].
Conclusions
Three SPRI biosensors specific for cystatin determi-
nation, based on the interaction between immobilized
Table 3. Cystatin concentration in urine of donors younger and older than 75
Donors under 75
Donor number Cystatin concentration in urine [mg/ml]
Sensor based on bromelain Sensor based on ficin Sensor based on chymopapain
  1 0.091 ± 0.004 0.091 ± 0.004 0.092 ± 0.001
  2 0.101 ± 0.010 0.100 ± 0.006 0.103 ± 0.008
  3 0.155 ± 0.001 0.154 ± 0.002 0.153 ± 0.005
  4 0.132 ± 0.001 0.132 ± 0.003 0.131 ± 0.006
  5 0.142 ± 0.010 0.136 ± 0.006 0.136 ± 0.002
Donors over 75
Donor number Cystatin concentration in urine [mg/ml]
Sensor based on bromelain Sensor based on ficin Sensor based on chymopapain
  6 0.080 ± 0.005 0.081 ± 0.006 0.087 ± 0.003
  7 0.112 ± 0.001 0.111 ± 0.001 0.113 ± 0.012
  8 0.130 ± 0.008 0.125 ± 0.004 0.129 ± 0.001
  9 0.132 ± 0.001 0.132 ± 0.009 0.134 ± 0.001
10 0.171 ± 0.007 0.174 ± 0.007 0.171 ± 0.010
Table 4. Cystatin concentration in saliva of donors
Donor number Cystatin concentration in saliva [mg/ml]
Sensor based on bromelain Sensor based on ficin Sensor based on chymopapain
1 0.60 ± 0.02 0.58 ± 0.03 0.58 ± 0.03
2 0.65 ± 0.04 0.66 ± 0.03 0.68 ± 0.02
3 0.65 ± 0.02 0.66 ± 0.02 0.67 ± 0.04
4 0.49 ± 0.04 0.47 ± 0.01 0.47 ± 0.03
5 0.79 ± 0.05 0.77 ± 0.03 0.78 ± 0.05
6 0.57 ± 0.05 0.56 ± 0.05 0.57 ± 0.03
bromelain, ficin or chymopapain with cystatin, have
been developed.
All three developed biosensors ensure the specif-
ic analytical response of cystatin. The optimum pH
for all three biosensors is between 6.3 and 6.6. Cali-
bration curves of cystatin for all three biosensors are
almost identical and exhibit a Langmuir type with
a roughly linear section between 0.1 and 0.6 mg/ml.
All three developed biosensors can be used success-
fully for the determination of cystatin concentration
in body fluids such as saliva, blood or urine.
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